Protara Therapeutics (NASDAQ: TARA) adds Funicular Funds to 21.7M-share resale
Rhea-AI Filing Summary
Protara Therapeutics, Inc. filed a prospectus supplement updating its existing resale registration covering up to 21,686,760 shares of common stock. These shares include currently held common stock as well as shares issuable upon exercise of pre-funded warrants and common warrants held by selling stockholders.
The update adds Funicular Funds, LP as a selling stockholder following an assignment on January 28, 2026 by OTA Trading Fund 1 LLC of common warrants exercisable for up to 142,400 common stock warrant shares. Funicular Funds, LP does not own common stock as of January 30, 2026 and is subject to a 4.99% beneficial ownership limitation after warrant exercises.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does Protara Therapeutics (TARA) register in this 424B7 supplement?
Protara updates a resale registration for up to 21,686,760 common shares. The registration covers existing shares, plus shares issuable from pre-funded warrants and common warrants, enabling named selling stockholders to resell these securities over time, subject to applicable securities laws.
Who is the new selling stockholder added for Protara Therapeutics (TARA)?
Funicular Funds, LP is added as a new selling stockholder. It appears following an assignment on January 28, 2026 from OTA Trading Fund 1 LLC of common warrants exercisable for up to 142,400 shares of Protara common stock, all included in the existing resale registration.
Does Funicular Funds, LP currently own Protara Therapeutics (TARA) common stock?
The table shows Funicular Funds, LP with no common shares owned as of January 30, 2026. Its interest consists of warrants exercisable for up to 142,400 common shares, which are registered for potential resale under the updated prospectus supplement.
What is the 4.99% beneficial ownership limitation for Protara (TARA)?
Funicular Funds, LP is subject to a 4.99% beneficial ownership limitation. This provision restricts warrant exercises so that, after giving effect to any exercise, the holder’s beneficial ownership of Protara common stock does not exceed 4.99% of the outstanding shares.